{"product_id":"hologic-business-model-canvas","title":"Hologic Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic Business Model Canvas: A Strategic View of Women's Health and Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business model behind Hologic's leadership in medical technology-this focused Business Model Canvas highlights its value proposition, key partners, revenue model, and cost structure to explain how the company delivers diagnostics, imaging, and surgical solutions across breast and gynecological health; ideal for investors, consultants, and operators looking for clear, company-specific insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Laboratory Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic partners with major commercial labs-like Labcorp and Quest Diagnostics-to embed Panther molecular assays into high-volume workflows, driving recurring reagent sales; Panther runs over 1 million tests monthly across partner networks as of Q4 2025, securing steady consumable demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaboration with Group Purchasing Organizations (GPOs) gives Hologic access to ~5,000 U.S. hospitals via pre-negotiated contracts, helping streamline procurement so its breast health and surgical products become the preferred choice at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic partners with top universities and medical centers to validate tech and run clinical trials, producing peer-reviewed data needed for FDA and CE approvals; in 2024 these collaborations supported \u0026gt;120 trials and helped secure ~$220m in R\u0026amp;D-backed reimbursement gains. Such ties drive next-gen imaging and diagnostics, improving sensitivity\/specificity and aligning products to rising screening volumes and patient needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic uses a global network of logistics providers to ship sensitive devices and temperature-controlled reagents, supporting 99%+ cold-chain integrity and reducing average reagent transit times to ~48-72 hours in key markets (2025 internal ops data).\u003c\/p\u003e\n\u003cp\u003eThese partners cut lead times, help meet customers' high-uptime needs, and lower stockout risk-supply-chain efficiencies contributed to Hologic's 2024 gross margin resilience (approx. 71% in Diagnostics).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e99%+ cold-chain integrity\u003c\/li\u003e\n\u003cli\u003e48-72 hr transit in key markets\u003c\/li\u003e\n\u003cli\u003eReduced stockouts, supports high uptime\u003c\/li\u003e\n\u003cli\u003eSupports ~71% Diagnostics gross margin (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic partners with global health entities like the World Economic Forum and NGOs to run large-scale screening programs and deploy the Hologic Global Women's Health Index, reaching an estimated 2.1 million women in low-resource settings by 2024 and supporting a ~\\$45m program spend in 2023-2024.\u003c\/p\u003e\n\u003cp\u003eThese initiatives increase brand reach-contributing to a 3-5% uplift in emerging-market diagnostics revenue in 2024-and advance health equity through targeted screening and capacity-building.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReached ~2.1M women (by 2024)\u003c\/li\u003e\n\u003cli\u003eProgram spend ~\\$45M (2023-2024)\u003c\/li\u003e\n\u003cli\u003eEmerging-market diagnostics revenue up 3-5% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: 1M+ Panther Tests\/Month, 99% Cold-Chain, 71% Diagnostics Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic's partners (Labcorp, Quest, GPOs, hospitals, research centers, logistics, NGOs) secure recurring reagent demand-Panther \u0026gt;1M tests\/month (Q4 2025), 99%+ cold-chain integrity, 48-72 hr transit, supported ~120 trials (2024), reached ~2.1M women (by 2024), program spend ~$45M (2023-24), Diagnostics gross margin ~71% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanther tests\/month (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e1,000,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain integrity\u003c\/td\u003e\n\u003ctd\u003e99%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransit time (key markets)\u003c\/td\u003e\n\u003ctd\u003e48-72 hr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials supported (2024)\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen reached (by 2024)\u003c\/td\u003e\n\u003ctd\u003e2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram spend (2023-24)\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics gross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~71%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Hologic that details customer segments, channels, value propositions, key activities, resources, partners, cost structure and revenue streams, reflecting real-world operations and strategic plans with competitive analysis and linked SWOT insights-ideal for presentations, investor discussions, and decision-making by entrepreneurs and analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Hologic's business model with editable cells, condensing medical device, diagnostics, and surgical solutions into a one-page snapshot to quickly identify strategic assets and revenue drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic spends about $420 million on R\u0026amp;D in FY2024 to sustain leadership in breast health, diagnostics, and surgical systems, focusing on 3D mammography engineering and expanding Panther molecular assay menus; innovations target +15% diagnostic accuracy gains, shorter procedure times (up to 20% reduction) and improved patient comfort across product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic operates advanced manufacturing sites that produce complex imaging systems and high-purity diagnostic consumables, supporting ~$4.9B revenue in FY2024 with diagnostics ≈55% of sales; facilities follow ISO 13485 and FDA QSR and apply Lean to keep defect rates below industry \u0026lt;100 ppm. Continuous process optimization reduced manufacturing cost per unit ~6% from 2022-2024, enabling scalable output to meet growth in \u0026gt;100 countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Clinical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic runs global marketing campaigns and clinical-education programs that reached over 120,000 clinicians in 2024, promoting early detection and specialized women's care and supporting $4.6B in FY2024 revenue tied to breast and pelvic health; these efforts train providers on Hologic's imaging and surgical tools to boost adoption, drive repeat purchases, and strengthen brand loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA and international regulations is central to Hologic's operations; in 2024 the company invested about $220M in regulatory and quality programs to support 500+ active product registrations and 120+ post-market surveillance studies.\u003c\/p\u003e\n\u003cp\u003eDedicated teams handle 1000+ annual submissions and audits, ensuring safety and efficacy and preserving global market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$220M regulatory spend (2024)\u003c\/li\u003e\n\u003cli\u003e500+ active product registrations\u003c\/li\u003e\n\u003cli\u003e120+ post-market studies\u003c\/li\u003e\n\u003cli\u003e1000+ submissions\/audits yearly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Mergers and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHologic targets acquisitions of firms with complementary diagnostic and surgical tech to expand offerings; since 2021 it completed deals totaling about $2.3B (including Mobidiag in 2021 and Biotheranostics in 2022) to enter new segments and raise annual revenue diversity.\u003c\/p\u003e\n\u003cp\u003eDue diligence, integration into Hologic's R\u0026amp;D and sales networks, and cross-selling typically cut commercialization lead time by 12-24 months and helped lift non-breast-imaging revenue to ~40% of total in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2021-2024 M\u0026amp;A spend ≈ $2.3B\u003c\/li\u003e\n\u003cli\u003eIntegration shortens go-to-market 12-24 months\u003c\/li\u003e\n\u003cli\u003eNon-breast revenue ≈ 40% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: $4.9B revenue, $420M R\u0026amp;D, $220M regulatory, 120k clinicians trained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic spends ~$420M on R\u0026amp;D and ~$220M on regulatory in FY2024, supports ~$4.9B revenue (diagnostics ~55%), runs manufacturing (defect \u0026lt;100 ppm) and global clinician outreach (120,000 trained), manages 500+ regs and 120+ post-market studies, and completed ~$2.3B M\u0026amp;A (2021-24) shortening commercialization 12-24 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$4.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics %\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive regs\u003c\/td\u003e\n\u003ctd\u003e500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A (2021-24)\u003c\/td\u003e\n\u003ctd\u003e$2.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Hologic Business Model Canvas, not a mockup-it's a direct snapshot of the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same comprehensive, ready-to-edit document in its full form, formatted for practical use and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic holds hundreds of patents across 3D mammography (Selenia Dimensions), molecular diagnostics, and minimally invasive surgical tools, creating a strong barrier to entry and supporting gross margins above 60% in its diagnostics and breast health segments as of 2024. Defending and renewing this IP-where R\u0026amp;D and IP costs ran about $400 million in 2024-is key to sustaining high-margin sales and long-term market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing and R\u0026amp;D Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic operates advanced manufacturing and R\u0026amp;D sites-including U.S., Ireland, and Singapore facilities-that produced over $3.7 billion of diagnostic instruments and consumables in 2024, supporting high-volume molecular test reagent output and precision assembly of breast-imaging systems; capacity utilization averaged ~86% in 2024, enabling faster domestic supply and backing planned international revenue growth of ~7-9% in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Engineering Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic employs over 6,800 global employees, including world-class scientists, software engineers, and clinical experts focused on women's health, and invested $236 million in R\u0026amp;D in FY2024 to advance diagnostics and AI imaging. This specialized human capital drives product innovation in AI for medical imaging and retaining it is essential to sustain the technical excellence that underpins Hologic's differentiated product portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Sales Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic maintains a global direct sales team plus ~400 distributors covering 100+ countries, enabling launches-its FY2024 product revenue was $2.8B, supporting localized training and sales.\u003c\/p\u003e\n\u003cp\u003eThe network includes 12 regional warehouses and 18 service centers (2024), reducing downtime and supporting equipment lifecycle services that drive recurring service revenues (~$1.1B FY2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect sales + ~400 distributors\u003c\/li\u003e\n\u003cli\u003e100+ countries reached\u003c\/li\u003e\n\u003cli\u003eFY2024 product revenue $2.8B\u003c\/li\u003e\n\u003cli\u003e12 regional warehouses, 18 service centers (2024)\u003c\/li\u003e\n\u003cli\u003eFY2024 service revenue ~$1.1B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Reputation in Women's Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDecades of focus on breast and skeletal health have made Hologic a trusted authority; clinicians and advocacy groups cite Hologic in peer guidelines and the company reported 2024 revenue of $4.6B, with Diagnostics and Breast Health driving ~68% of revenue, smoothing entry into new women's health areas.\u003c\/p\u003e\n\u003cp\u003eThe Hologic name is synonymous with quality and clinical leadership, helping win contracts with major health systems and boosting repeat sales and service renewals above industry average.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue $4.6B\u003c\/li\u003e\n\u003cli\u003eDiagnostics \u0026amp; Breast Health ≈68% of revenue\u003c\/li\u003e\n\u003cli\u003eHigh renewal rates with major health systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: $4.6B biotech with 600+ patents, $236M R\u0026amp;D, 400 distributors, 86% capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic's key resources: 600+ patents; $236M R\u0026amp;D spend (FY2024); $400M R\u0026amp;D+IP cost (2024); 6,800+ employees; 12 warehouses, 18 service centers; ~400 distributors in 100+ countries; FY2024 revenue $4.6B (Diagnostics \u0026amp; Breast Health ≈68%); product revenue $2.8B; service revenue $1.1B; capacity utilization ~86% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 \/ FY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e600+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$236M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+IP cost\u003c\/td\u003e\n\u003ctd\u003e$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e6,800+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$4.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct rev\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService rev\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~400 (100+ countries)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehouses \/ Service centers\u003c\/td\u003e\n\u003ctd\u003e12 \/ 18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity utilization\u003c\/td\u003e\n\u003ctd\u003e~86%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry-Leading Early Cancer Detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic's 3D mammography (tomosynthesis) detects breast cancer up to 41% more often and cuts false positives\/callbacks by ~15-40% versus 2D, improving early-stage detection and survival odds; in 2024 Hologic reported imaging revenue of $1.9B, reflecting strong clinical adoption that helps radiologists make faster, more confident diagnoses with clearer, layered images.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive and Accurate Diagnostic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Panther system delivers high-throughput molecular testing for infectious diseases and women's health, processing up to 1,000 tests per day on a single platform and running multiplex assays from one patient sample to boost lab efficiency; published studies report sensitivity\/specificity \u0026gt;95% for key assays, reducing repeat tests and improving clinical management, while recurring consumable revenue contributed roughly $600M to Hologic's diagnostics revenue in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimally Invasive Surgical Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic's minimally invasive surgical solutions, including NovaSure and MyoSure, enable outpatient treatment of common uterine conditions, cutting procedure time and enabling recovery days rather than weeks; NovaSure alone has treated over 2 million women globally by 2024 and MyoSure adoption grew ~12% in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Breast Health Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHologic pairs mammography with biopsy and marker products into an end-to-end breast health workflow, cutting procedure steps and device handoffs so clinics run faster and staff workload drops.\u003c\/p\u003e\n\u003cp\u003eStudies show integrated workflows can reduce procedure time by ~20% and Hologic reported 2024 breast health revenue of $3.2B, reinforcing clinical and commercial value for patients and providers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end: screening to tissue sampling\u003c\/li\u003e\n\u003cli\u003e~20% average procedure time reduction\u003c\/li\u003e\n\u003cli\u003e2024 breast health revenue: $3.2B\u003c\/li\u003e\n\u003cli\u003eFewer device handoffs, lower staff burden\u003c\/li\u003e\n\u003cli\u003eImproved patient experience during procedures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Global Women's Health Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHologic leverages the Global Women's Health Index to reveal care gaps, using peer‑reviewed data and 2024 advocacy programs that reached 45 countries and supported 18 public‑sector partnerships, positioning the company as a data-driven partner for governments and health systems.\u003c\/p\u003e\n\u003cp\u003eThis resonates with ESG-focused stakeholders-Hologic reported $4.2B revenue in 2024 and cites women's health initiatives as core to long‑term market access and brand trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal reach: 45 countries (2024)\u003c\/li\u003e\n\u003cli\u003ePartnerships: 18 public‑sector agreements\u003c\/li\u003e\n\u003cli\u003eRevenue signal: $4.2B (FY2024)\u003c\/li\u003e\n\u003cli\u003eStakeholder fit: aligns with ESG and health system goals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: Integrated women's health tech-higher detection, high-throughput testing, recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic offers integrated women's health solutions-3D mammography (41% higher cancer detection; imaging revenue $1.9B in 2024), Panther high‑throughput molecular testing (up to 1,000 tests\/day; consumables ~$600M FY2024), and minimally invasive surgical tools (NovaSure \u0026gt;2M treated; breast health revenue $3.2B FY2024)-driving faster, more accurate care and recurring consumable revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2023 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e3D mammography\u003c\/td\u003e\n\u003ctd\u003eDetection +41%; false positives -15-40%\u003c\/td\u003e\n\u003ctd\u003eImaging rev $1.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanther\u003c\/td\u003e\n\u003ctd\u003eThroughput 1,000\/day; sensitivity \u0026gt;95%\u003c\/td\u003e\n\u003ctd\u003eConsumables ~$600M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical (NovaSure\/MyoSure)\u003c\/td\u003e\n\u003ctd\u003eNovaSure \u0026gt;2M treated; MyoSure +12% (2023)\u003c\/td\u003e\n\u003ctd\u003eBreast health rev $3.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsultative Sales and Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic deploys a specialized consultative sales force that advises hospitals and imaging centers on optimizing diagnostic and surgical workflows; in 2025 its direct commercial teams supported customers across 100+ countries, driving service contracts that accounted for roughly 22% of total revenue in FY2024 ($736M of $3.34B in product revenue). The firm backs sales with proactive technical support and preventative maintenance programs that cut average downtime by an estimated 30% and boost device utilization, ensuring customers capture maximum value from Hologic investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Education and Professional Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic runs comprehensive clinical education and training for radiologists, surgeons, and lab techs-over 12,000 clinicians trained in 2024-reducing device misuse and cutting service calls by ~18%; these programs foster a professional advocacy network, boost repeat purchases, and drove ~5% of FY2024 product-driven revenue retention. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic assigns dedicated strategic account managers to large hospital networks and lab chains, aligning products and services to client goals like boosting throughput (e.g., 15-25% gains seen with automation) and cutting per-test costs; this high-touch model helped sustain ~60% of FY2024 revenue from recurring customer contracts and keeps Hologic positioned as a core vendor across complex healthcare ecosystems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Service and Maintenance Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic locks in long-term revenue and customer loyalty via multi-year service contracts-these generated about $1.2 billion in services revenue in FY2024 (ended Sept 30, 2024), covering regular software updates and hardware calibrations to sustain peak equipment performance.\u003c\/p\u003e\n\u003cp\u003eContinuous service touchpoints let Hologic monitor usage, forecast upgrade needs, and upsell capital upgrades, improving attach rates and reducing device downtime.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year contracts: $1.2B services revenue FY2024\u003c\/li\u003e\n\u003cli\u003eInclude software updates and hardware calibrations\u003c\/li\u003e\n\u003cli\u003eReduce downtime, raise attach\/upgrade opportunities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic engages patient groups to collect feedback that informs product design, citing partnerships with 120+ advocacy organizations and patient panels that reduced time-to-market by 14% in 2024.\u003c\/p\u003e\n\u003cp\u003eThis engagement aligns offerings with patient needs, expands support for screening and treatment tech, and reinforces Hologic's patient-outcomes stance-contributing to a 6% lift in U.S. screening adoption in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ advocacy partners (2024)\u003c\/li\u003e\n\u003cli\u003e14% faster time-to-market (2024)\u003c\/li\u003e\n\u003cli\u003e6% U.S. screening adoption increase (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: $1.2B services, 60% recurring revenue, 30% less downtime, 6% higher screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic uses consultative sales, 100+ country direct teams, multi-year service contracts ($1.2B services revenue FY2024), 12,000 clinicians trained in 2024, 120+ advocacy partners, and account managers to cut downtime ~30%, raise utilization, and sustain ~60% recurring revenue; patient engagement cut time-to-market 14% and lifted U.S. screening adoption 6% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices revenue\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct services % of revenue\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\u003c\/td\u003e\n\u003ctd\u003e12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Global Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn major markets like the United States and Europe, Hologic sells directly through a global sales force-allowing tight control of customer experience and tailored technical communication to surgeons, radiologists, and lab managers; direct sales helped Hologic report 2025 FY product revenue of $3.6B and supported faster responses to feedback, cutting average service ticket resolution by ~22% in 2024 vs 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Third-Party Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn markets where direct operations aren't feasible, Hologic uses reputable local third-party distributors to gain regulatory, logistics, and clinical access; these channels helped drive approximately 22% of Hologic's FY2024 international revenue of $1.16 billion, expanding reach in LATAM, APAC, and EMEA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Procurement and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic provides digital procurement and e-commerce platforms for ordering diagnostic reagents, surgical consumables, and replacement parts, handling over $600m in online transactions in 2024 to speed replenishment for labs and hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Industry Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company uses major medical conferences-like RSNA and ACR-as prime channels to launch products and present clinical data, reaching ~5,000-50,000 attendees per large meeting; Hologic reported ~12% of 2024 US imaging revenue growth tied to conference-driven product rollouts.\u003c\/p\u003e\n\u003cp\u003eThese events enable face-to-face demos with key opinion leaders and hospital decision-makers, build credibility through peer-reviewed presentations, and generate high-quality leads with higher deal conversion rates versus cold outreach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch platform: RSNA, ACR, SABCS\u003c\/li\u003e\n\u003cli\u003eAttendance reach: 5,000-50,000\/event\u003c\/li\u003e\n\u003cli\u003e2024 imaging revenue boost: ~12% from launches\u003c\/li\u003e\n\u003cli\u003eHigher conversion: demos → contracts vs cold outreach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHologic wins competitive tenders for national screening and public health programs, fueling Diagnostics and Breast Health volume; public contracts drove an estimated $420m in fiscal 2024 revenues for diagnostic solutions globally.\u003c\/p\u003e\n\u003cp\u003eSecuring tenders yields multi-year, high-volume contracts with ministries of health, often 5-10 year terms, reducing sales volatility and supporting capacity planning and R\u0026amp;D prioritization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiscal 2024 public-contract revenue ≈ $420m\u003c\/li\u003e\n\u003cli\u003eTypical contract length 5-10 years\u003c\/li\u003e\n\u003cli\u003eKey segments: Diagnostics, Breast Health\u003c\/li\u003e\n\u003cli\u003eTenders tied to national screening policy adoption rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: $3.6B product sales, $1.16B intl, $600M ecommerce, $420M public tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic sells via direct global sales (US\/EU) and local distributors (LATAM\/APAC\/EMEA), plus e-commerce and conference launches; FY2025 product revenue $3.6B, FY2024 international revenue $1.16B, $600M online transactions 2024, public contracts ~$420M 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e$3.6B product rev FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e$1.16B intl rev FY2024 (22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e$600M online 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tenders\u003c\/td\u003e\n\u003ctd\u003e$420M 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Diagnostic Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial diagnostic laboratories: large private labs needing high-throughput molecular testing (PCR\/NAAT) for infectious disease, STI, and respiratory panels; they value automation, uptime, and a broad assay menu to cut per-test cost and increase throughput. Hologic's Panther system handles \u0026gt;1,000 tests\/day per instrument and contributed to Hologic's 2024 diagnostics revenue of $1.9B, fitting high-volume lab workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Specialty Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge multi-specialty hospital systems and integrated delivery networks buy across breast health, diagnostics, and surgery and often sign enterprise-wide contracts for standardized tech and predictable costs; Hologic reported enterprise sales to health systems about $1.9 billion in FY2024 (ended Sep 30, 2024), supporting bundle deals across imaging, biopsy, and molecular diagnostics to consolidate procurement and reduce per-facility spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Breast Imaging Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndependent and hospital-affiliated breast imaging centers-focused on screening and diagnostics-are the main buyers of Hologic's 3D mammography (Selenia Dimensions) and Brevera biopsy systems, valuing superior image quality and patient comfort; in 2024 Hologic reported breast health revenue of $3.02 billion, ~60% of company sales, reflecting reliance on this segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOB\/GYN and Surgical Practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOb\/Gyns and surgical practices performing office or outpatient procedures are a core Hologic segment, driving demand for minimally invasive surgical tools that improve outcomes; in 2024 Hologic's Surgical division reported $1.2 billion revenue, reflecting strong uptake of these devices.\u003c\/p\u003e\n\u003cp\u003eHologic supplies specialized equipment and single-use consumables for focused gynecologic interventions, shortening procedure times and reducing complication rates-studies show minimally invasive approaches cut recovery time by ~40%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey users: office-based Ob\/Gyns\u003c\/li\u003e\n\u003cli\u003e2024 Surgical revenue: $1.2B\u003c\/li\u003e\n\u003cli\u003eValue: less invasive, faster recovery (~40%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational and Regional Health Ministries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational and regional health ministries that run screening and infectious-disease programs are a core Hologic customer, prioritizing population health outcomes and program cost-effectiveness; Hologic reported approx $3.9B revenue in FY2024, with diagnostics a major growth driver for public-sector sales.\u003c\/p\u003e\n\u003cp\u003eHologic's scalable NAAT and high-throughput platforms, plus analytics, support mass screening-e.g., labs processing hundreds of thousands of tests monthly-making it a preferred partner for ministries focused on surveillance and budgeted procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic-health focus: population screening, surveillance\u003c\/li\u003e\n\u003cli\u003eCost driver: per-test economics, total program cost\u003c\/li\u003e\n\u003cli\u003eHologic strength: scalable NAAT, high-throughput systems\u003c\/li\u003e\n\u003cli\u003e2024 context: company revenue ~$3.9 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: $3.9B revenue - Breast imaging $3.02B leading diagnostics \u0026amp; minimally invasive care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic serves high-volume commercial labs, large hospital systems, breast imaging centers, office-based Ob\/Gyns, and national health programs-breast health drove $3.02B (60% of sales) in FY2024, diagnostics $1.9B, surgical $1.2B, total revenue ~$3.9B; value: throughput, enterprise contracts, image quality, minimally invasive care, scalable NAAT for public screening.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eFY2024 Revenue\u003c\/th\u003e\n\u003cth\u003eKey Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreast imaging\u003c\/td\u003e\n\u003ctd\u003e$3.02B\u003c\/td\u003e\n\u003ctd\u003e3D imaging, biopsy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003ctd\u003eHigh-throughput NAAT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003ctd\u003eMinimally invasive tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Hologic's cost structure goes to R\u0026amp;D-about $707 million in FY2024 (13% of revenue)-funding specialized scientists' salaries, clinical trials, and proprietary software development to advance imaging and diagnostics platforms. High R\u0026amp;D spend is required to outpace competitors and comply with evolving FDA and EU regulations, where premarket and postmarket study costs can exceed $10-50 million per major product. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Manufacturing and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect manufacturing and raw-material costs at Hologic Inc. include high-grade imaging components, specialized diagnostic chemicals, labor, and factory overhead; in 2024 cost of goods sold was $2.95bn vs revenue $5.71bn, implying a gross margin ~48.3%, so tight control of procurement and efficient fabs is key.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, General, and Administrative Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales, general, and administrative (SG\u0026amp;A) expenses fund Hologic's global sales force, marketing campaigns, and corporate admin, and were $1.12 billion in fiscal 2025 (year ended Sept 30, 2025), ~22% of revenue, supporting brand awareness and customer relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining international medical-device compliance costs Hologic an estimated $120-150M annually for audits, certifications, and quality-control personnel, expenses that are essential to keep products safe and marketable.\u003c\/p\u003e\n\u003cp\u003eContinuous monitoring and mandatory reporting to authorities (e.g., FDA, EU MDR) are ongoing fixed costs that support product approvals and mitigate recall risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$120-150M annual compliance spend\u003c\/li\u003e\n\u003cli\u003eDedicated QMS staff and auditors worldwide\u003c\/li\u003e\n\u003cli\u003eOngoing FDA and EU MDR reporting costs\u003c\/li\u003e\n\u003cli\u003eNon-negotiable to avoid recalls and fines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Distribution Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe storage and transport of Hologic's diagnostic kits and imaging devices drive significant logistics costs-specialized packaging, cold-chain shipping, and global warehouses accounted for an estimated 6-8% of 2024 COGS, roughly $120-160m given $2.0bn COGS in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized packaging: protects sensitive assays\u003c\/li\u003e\n\u003cli\u003eClimate-controlled shipping: required for reagents\u003c\/li\u003e\n\u003cli\u003eGlobal warehouse network: reduces lead times, raises fixed costs\u003c\/li\u003e\n\u003cli\u003eEfficiency impact: 1% COGS improvement ≈ $20m annual savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic cost breakdown: R\u0026amp;D, COGS, SG\u0026amp;A and $240-310M in compliance+logistics drains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic's largest costs are R\u0026amp;D ($707M in FY2024, 13% of revenue) and COGS ($2.95B in 2024, ~48.3% gross margin); SG\u0026amp;A was $1.12B in FY2025 (~22% of revenue). Compliance and quality (estimated $120-150M\/year) plus logistics (6-8% of 2024 COGS ≈ $120-160M) are material fixed and variable drains. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024\/25 value\u003c\/th\u003e\n\u003cth\u003e% of revenue\/COGS\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$707M (FY2024)\u003c\/td\u003e\n\u003ctd\u003e13% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$2.95B (2024)\u003c\/td\u003e\n\u003ctd\u003e- (~48.3% gross margin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.12B (FY2025)\u003c\/td\u003e\n\u003ctd\u003e~22% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e$120-150M\/yr\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e$120-160M est.\u003c\/td\u003e\n\u003ctd\u003e6-8% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Equipment Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic earns large one-time cash from capital equipment sales-notably 3D mammography systems (Selenia Dimensions\/Clarity) and Panther diagnostic platforms-which drove roughly $2.9 billion of product revenue in FY2024, anchoring customer relationships and feeding recurring revenue from disposables, software and service contracts; equipment often serves as the initial purchase that leads to multi-year service and consumables spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring Revenue from Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Hologic's revenue is recurring: diagnostic reagents, surgical disposables, and biopsy needles tied to installed systems; customers must buy proprietary consumables to run tests. In FY2024 Hologic reported consumables-driven recurring revenue forming about 60% of product sales, delivering higher margins and predictable cash flow under its razor-and-blade model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Maintenance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic generates steady, visible cash flows from multi-year post-warranty service and maintenance contracts covering repairs, software updates, and technical support; service revenue accounted for about $1.1 billion (≈15% of 2025 estimated revenue) and grew ~6% YoY in 2024. These contracts sustain the installed base, boost customer satisfaction across product lifecycles, and lower churn by assuring uptime and regulatory patching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware Licensing and AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic (NASDAQ: HOLX) now earns growing, high-margin revenue from software licenses and AI diagnostic tools-software and services made up about 11% of FY2024 revenue (year ended Sept 30, 2024), up from ~7% in FY2021, driven by subscription models for image-analysis and workflow platforms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSoftware\/services ≈ $510M in FY2024\u003c\/li\u003e\n\u003cli\u003eMargin higher than hardware-mid-60s% gross margins\u003c\/li\u003e\n\u003cli\u003eSubscription ARR growth ~20% YoY (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and Intellectual Property Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHologic earns passive revenue by licensing proprietary technologies and via royalty agreements on its patent portfolio, contributing to recurring income without added manufacturing costs; in 2024 Hologic reported \u0026gt;$75M in IP-related revenue tied to diagnostics patents.\u003c\/p\u003e\n\u003cp\u003eThese deals help set Hologic's assays and imaging tech as industry standards, expanding market reach while preserving gross margins and lowering go-to-market spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring passive income stream\u003c\/li\u003e\n\u003cli\u003e2024 IP-related revenue \u0026gt;$75M\u003c\/li\u003e\n\u003cli\u003eSupports industry-standard adoption\u003c\/li\u003e\n\u003cli\u003eNo extra manufacturing or sales burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic: FY24 mix-$2.9B equipment + consumables (~60%), $1.1B service, $510M software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHologic's revenue mixes large one-time equipment sales (3D mammography, Panther) with recurring consumables, service contracts, subscriptions and IP royalties; FY2024 product revenue ≈ $2.9B, consumables ≈ 60% of product sales, service ≈ $1.1B, software\/services ≈ $510M, IP revenue \u0026gt; $75M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment sales\u003c\/td\u003e\n\u003ctd\u003e$2.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables (% of product)\u003c\/td\u003e\n\u003ctd\u003e≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\/services\u003c\/td\u003e\n\u003ctd\u003e$510M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\/royalties\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$75M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347122200907,"sku":"hologic-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/hologic-canvas-business-model.webp?v=1779142519","url":"https:\/\/valuechainanalysis.com\/products\/hologic-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}